Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (NCT02923778)
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery (resectable). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- Mayo Clinic in Rochester — Rochester, Minnesota
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
- UT MD Anderson Cancer Center — Houston, Texas
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- University Health Network-Princess Margaret Hospital — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Leiomyosarcoma
- A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma — Basking Ridge, New Jersey
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma — Los Angeles, California
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) — Phoenix, Arizona
- A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions — Houston, Texas
- Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma — Santa Monica, California
Explore by condition: All Leiomyosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.